Eukaryotic expression vectors and immunoconjugates for cancer therapy

E. M. Glinka, E. F. Edelweiss, S. M. Deyev

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

This review considers ways to address specificity to therapeutic targeted anticancer agents. These include transcriptional activation of tissue-and tumor-specific promoters in eukaryotic expression vectors and use of antitumor-lirected immunoconjugates. The review deals with analysis of strategies used for selection of targeted promoters and examples of antibody fusion proteins exhibiting antitumor activity. A new direction in antitumor treatment pooling together methods of gene therapy and antibody therapy has appeared. This direction is based on the development of vectors encoding secreted forms of immunoconjugates. After vector introduction into a cell, the latter is capable of synthesizing and secreting antibody fusion protein composed of a therapeutic anticancer agent and antibody specifically targeted to cancer cells.

Original languageEnglish
Pages (from-to)597-606
Number of pages10
JournalBiochemistry (Moscow)
Volume71
Issue number6
DOIs
Publication statusPublished - Jun 2006
Externally publishedYes

Fingerprint

Immunoconjugates
Antibodies
Antineoplastic Agents
Neoplasms
Fusion reactions
Gene therapy
Therapeutics
Genetic Therapy
Carcinogens
Transcriptional Activation
Tumors
Proteins
Chemical activation
Cells
Tissue
Direction compound

Keywords

  • Anticancer agent
  • Fusion protein
  • Gene therapy
  • Immunoconjugate
  • Secreted protein

ASJC Scopus subject areas

  • Biochemistry

Cite this

Eukaryotic expression vectors and immunoconjugates for cancer therapy. / Glinka, E. M.; Edelweiss, E. F.; Deyev, S. M.

In: Biochemistry (Moscow), Vol. 71, No. 6, 06.2006, p. 597-606.

Research output: Contribution to journalReview article

Glinka, E. M. ; Edelweiss, E. F. ; Deyev, S. M. / Eukaryotic expression vectors and immunoconjugates for cancer therapy. In: Biochemistry (Moscow). 2006 ; Vol. 71, No. 6. pp. 597-606.
@article{9fe36924e3384a4a9bbc772940e1a81e,
title = "Eukaryotic expression vectors and immunoconjugates for cancer therapy",
abstract = "This review considers ways to address specificity to therapeutic targeted anticancer agents. These include transcriptional activation of tissue-and tumor-specific promoters in eukaryotic expression vectors and use of antitumor-lirected immunoconjugates. The review deals with analysis of strategies used for selection of targeted promoters and examples of antibody fusion proteins exhibiting antitumor activity. A new direction in antitumor treatment pooling together methods of gene therapy and antibody therapy has appeared. This direction is based on the development of vectors encoding secreted forms of immunoconjugates. After vector introduction into a cell, the latter is capable of synthesizing and secreting antibody fusion protein composed of a therapeutic anticancer agent and antibody specifically targeted to cancer cells.",
keywords = "Anticancer agent, Fusion protein, Gene therapy, Immunoconjugate, Secreted protein",
author = "Glinka, {E. M.} and Edelweiss, {E. F.} and Deyev, {S. M.}",
year = "2006",
month = "6",
doi = "10.1134/S0006297906060022",
language = "English",
volume = "71",
pages = "597--606",
journal = "Biochemistry. Biokhimiia",
issn = "0006-2979",
publisher = "Maik Nauka-Interperiodica Publishing",
number = "6",

}

TY - JOUR

T1 - Eukaryotic expression vectors and immunoconjugates for cancer therapy

AU - Glinka, E. M.

AU - Edelweiss, E. F.

AU - Deyev, S. M.

PY - 2006/6

Y1 - 2006/6

N2 - This review considers ways to address specificity to therapeutic targeted anticancer agents. These include transcriptional activation of tissue-and tumor-specific promoters in eukaryotic expression vectors and use of antitumor-lirected immunoconjugates. The review deals with analysis of strategies used for selection of targeted promoters and examples of antibody fusion proteins exhibiting antitumor activity. A new direction in antitumor treatment pooling together methods of gene therapy and antibody therapy has appeared. This direction is based on the development of vectors encoding secreted forms of immunoconjugates. After vector introduction into a cell, the latter is capable of synthesizing and secreting antibody fusion protein composed of a therapeutic anticancer agent and antibody specifically targeted to cancer cells.

AB - This review considers ways to address specificity to therapeutic targeted anticancer agents. These include transcriptional activation of tissue-and tumor-specific promoters in eukaryotic expression vectors and use of antitumor-lirected immunoconjugates. The review deals with analysis of strategies used for selection of targeted promoters and examples of antibody fusion proteins exhibiting antitumor activity. A new direction in antitumor treatment pooling together methods of gene therapy and antibody therapy has appeared. This direction is based on the development of vectors encoding secreted forms of immunoconjugates. After vector introduction into a cell, the latter is capable of synthesizing and secreting antibody fusion protein composed of a therapeutic anticancer agent and antibody specifically targeted to cancer cells.

KW - Anticancer agent

KW - Fusion protein

KW - Gene therapy

KW - Immunoconjugate

KW - Secreted protein

UR - http://www.scopus.com/inward/record.url?scp=33745296667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745296667&partnerID=8YFLogxK

U2 - 10.1134/S0006297906060022

DO - 10.1134/S0006297906060022

M3 - Review article

AN - SCOPUS:33745296667

VL - 71

SP - 597

EP - 606

JO - Biochemistry. Biokhimiia

JF - Biochemistry. Biokhimiia

SN - 0006-2979

IS - 6

ER -